Recurrence of duodenal ulceration in patients on maintenance sucralfate. A 12-month follow-up study.
A single-blind, 1-year follow-up study of 70 patients with recently healed duodenal ulcers was undertaken to assess the value of sucralfate (Ulsanic; Continental Ethicals) in preventing recurrence and to establish the lowest dose required to achieve this. Endoscopy was repeated on clinical relapse and routinely at 6 and 12 months. Fifty of the 70 patients were followed up for 12 months or to recurrence proved on endoscopy; the remaining 20 patients were excluded from analysis because of default or protocol violation. Endoscopic evidence of recurrence was found in 6 of 19 patients (32%) given sucralfate 1 g twice a day (group B), in 7 of 15 (47%) on sucralfate 1 g at night (group A), and in 13 of 16 controls (81%). The recurrence rates in groups A and B were significantly lower than in the control group (P less than 0,05 and P less than 0,005 respectively), and there was a significant gradient between the number of patients in remission at 12 months and the amount of medication (P less than 0,05).
D000328:Adult; D000535:Aluminum / Q000008:administration & dosage / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012907:Smoking; D013392:Sucralfate
D000897:Anti-Ulcer Agents; D013392:Sucralfate; D000535:Aluminum